ZVRA 株価分析 — Zevra Therapeutics Inc. (Healthcare >> Biotechnology)
ZVRA に関するよくある質問
ZVRAのPER(株価収益率)は?
Zevra Therapeutics Inc.(ZVRA)は現在PER 4.76倍で取引されています。
ZVRAのROE(自己資本利益率)は?
Zevra Therapeutics Inc.のROEは60.36%です。
ZVRAの配当利回りは?
Zevra Therapeutics Inc.の配当利回りは0.00%です。
ZVRAの品質スコア(Quality Score)は?
当社のAIはZVRAの総合財務品質を100点中77点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
ZVRAは今が買い時ですか?
当社AIのタイミングスコアは100点中28点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
ZVRAはどのセクターに属しますか?
Zevra Therapeutics Inc.はHealthcare >> Biotechnologyセクターに分類されます(NASDAQ市場)
ZVRA AI Analysis Summary
Our AI summary for ZVRA: Zevra Therapeutics Inc. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 4.76, ROE of 60.36%, a dividend yield of 0.00%. Its financial Quality Score stands at 77/100 — mid-range fundamentals relative to the market. The AI Timing Score is 28/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 10.52
Price
0.47
(4.62%)
Day Change
|
|
|---|
ZVRA, ファンダメンタルスコアはgood ( ファンダメンタル = 77) but テクニカルスコアは ...(Sign In to See)...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Good
- Reason
-
平均ROEが低い
ROAの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are ok , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
66% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
63
GOOD
|
| Magic Formula Rank by ROE |
63
GOOD
|
| Magic Formula Rank by ROIC |
76
GOOD
|
| Price | 10.52 |
| PBV / Sector |
2.89 / 44,022.72
|
| Earning Per Share | 2.20 |
| PE / Sector |
4.76 / 19.17
GREAT
|
| PEG or PE/Growth / Sector |
-0.69 / 1.24
|
| Average 1M Daily Value |
17.89 M
GREAT
|
| Average 1W Daily Value |
13.64 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
66% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-05 08:01:08 |
| Symbol | ZVRA |
| Name | ZEVRA THERAPEUTICS INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 59.12 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 594.40 / 9,586.08 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 101 Federal Street, Boston, MA, United States, 02110
Phone: 888 958 1253
Website: https://www.zevra.com
Employees: 61
Sector: Healthcare >> Biotechnology
Description: Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google